Conferences DDW 2014
Other Infections
DDW 2014: Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
- Details
- Category: HBV/HCV Coinfection
- Published on Wednesday, 28 May 2014 00:00
- Written by Liz Highleyman
Among HBV/HCV coinfected people, about half have dominant hepatitis B virus while half have dominant hepatitis C, and those with active HBV replication are at higher risk of liver-related complications and death, according to study findings presented at Digestive Disease Week this month in Chicago.
DDW 2014: Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 18 May 2014 00:00
- Written by Liz Highleyman
Some factors traditionally associated with poorer response to interferon-based therapy for hepatitis C played little role in clinical trials of the HCV protease inhibitor faldaprevir, according to several studies presented at Digestive Disease Week this month in Chicago. HCV subtype 1a and prior treatment did not significantly worsen response, while HIV/HCV coinfection may be associated with better response.
New Hepatitis C Treatments Highlighted at Digestive Disease Week
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
Direct-acting antiviral agents for hepatitis C were a key theme of Digestive Disease Week 2014, taking place this week in Chicago. While the conference covers all aspects of gastroenterology and hepatology, new treatments that can cure more than 90% of chronic hepatitis C patients with few side effects in as little as 8 to 12 weeks are bringing about a revolution in the field.
DDW 2014 and EASL 2014: Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
- Details
- Category: Liver Decompensation
- Published on Sunday, 18 May 2014 00:00
- Written by Liz Highleyman
The antibiotic rifaximin may help prevent or improve hepatic encephalopathy and bleeding varices in people with decompensated liver disease, according to studies presented at the recent EASL International Liver Congress and Digestive Disease Week.
DDW 2014: Drinking More Coffee Is Associated with Less Liver Fibrosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
People with hepatitis C who drink more cups of coffee per day may have a lower likelihood of developing advanced liver fibrosis or cirrhosis -- but only if it contains caffeine, and tea does not appear to have a similar effect, according to a study presented at the Digestive Disease Week (DDW 2014) meeting this week in Chicago.
DDW 2014: Sustained Response to Interferon Is Durable in Children with Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 May 2014 00:00
- Written by Liz Highleyman
Children with hepatitis C treated with interferon-based therapy continued to show undetectable HCV viral load up to 7 years after achieving sustained virological response in the PEDS-C trial, researchers reported at Digestive Disease Week this month in Chicago.
DDW 2014: Some Hepatitis B Patients Can Stop Antiviral Treatment without Relapse
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
Stopping antiviral therapy after several years appears generally safe for people with HBeAg negative chronic hepatitis B without liver cirrhosis, and a substantial proportion do not experience viral relapse or worsening liver inflammation while off treatment, according to a pair of posters presented at the Digestive Disease Week (DDW 2014) meeting this week in Chicago.
DDW 2014: AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 12 May 2014 00:00
- Written by Liz Highleyman
AbbVie's all-oral "3D" regimen containing ABT-450, ombitasvir, and dasabuvir, used with or without ribavirin, led to sustained virological response in 90% to 100% of genotype 1a and 1b hepatitis C patients in the Phase 3 PEARL trials, according to data reported at the Digestive Disease Week (DDW 2014) meeting last week in Chicago and in the May 4 online edition of the New England Journal of Medicine.
Web Design and Development by